Company Interview / Dreaming big: Compumedics posts record 1H sales

David Lawson from Compumedics (ASX: CMP) shares that their recent record sales orders for the first half of FY 25 are driven by growth in the US market. The introduction of key individuals to their US sales team bolsters the company's success, especially in the sleep diagnostics segment.

David highlights the standout performance of the Somfit home sleep testing device, which competes in the rapidly expanding US market for home sleep tests. With superior technology capturing true sleep architecture, Compumedics (ASX: CMP) aims to offer a cost-effective, integrated solution globally.

He notes that Compumedics (ASX: CMP) is on track with financials, with $32.8 million in orders for 1H and a focus on expanded opportunities in neurology, including EEG and MEG systems in the US, Europe, and Asia. The company maintains a revenue guidance of $55 million plus for FY 25.